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Abstract
Background: Comprehensive capture of Adverse Events (AEs) is crucial for monitoring for side effects of a therapy
while assessing efficacy. For cancer studies, the National Cancer Institute has developed the Common Terminology
Criteria for Adverse Events (CTCAE) as a required standard for recording attributes and grading AEs. The AE
assessments should be part of the Electronic Health Record (EHR) system; yet, due to patient-centric EHR design
and implementation, many EHR’s don’t provide straightforward functions to assess ongoing AEs to indicate a
resolution or a grade change for clinical trials.
Methods: At UAMS, we have implemented a standards-based Adverse Event Reporting System (AERS) that is
integrated with the Epic EHR and other research systems to track new and existing AEs, including automated lab
result grading in a regulatory compliant manner. Within a patient’s chart, providers can launch AERS, which opens
the patient’s ongoing AEs as default and allows providers to assess (resolution/ongoing) existing AEs. In another
tab, it allows providers to create a new AE. Also, we have separated symptoms from diagnoses in the CTCAE to
minimize inaccurate designation of the clinical observations. Upon completion of assessments, a physician would
submit the AEs to the EHR via a Health Level 7 (HL7) message and then to other systems utilizing a
Representational State Transfer Web Service.
Conclusions: AERS currently supports CTCAE version 3 and 4 with more than 65 cancer studies and 350 patients
on those studies. This type of standard integrated into the EHR aids in research and data sharing in a compliant,
efficient, and safe manner.
Background
Data collection in cancer research studies is vital to
understand the possible side effects of medication, the
medication’s efficacy, and overall safety in patients. Col-
lecting AEs has become problematic with the use of
both data management systems and EHR to record and
monitor the adverse events in the study population.
From the time the clinician documents the encounter
with the study participant to the data entry into the
database, there are several potential sites for AEs to be
duplicated, incompletely documented, or transcribed
incorrectly.
The Food and Drug Administration’s Code of Federal
Regulations Title 21 Section 312.64 requires investiga-
tors to immediately report any event to the sponsor
regardless of the relationship to the drug [1]. When Bel-
knap et al compared several nationwide cancer institutes
looking at the quality of methods of adverse event
reporting, they found zero of the 49 institutes “use a
valid method for assessing causality,” and 38 of the 49
are implicitly prompting global introspection by the
investigator [2]. Only one-third of the forms provided
the domain of terms recommended by the Food and
Drug Administration for the assessment of quality.
Belknap et al also noted that an integration of taxonomy
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system to CTCAE could help amend some of the issues
within adverse event reporting. They recommended that
because of the familiarity of the oncologist to use CTCAE
[2]. The findings of Belknap reiterate the finding from a
report in the Institute of Medicine on the national cancer
clinical trials system. The report states that “the lack of a
standard required data set leads to inconsistency in the
data collected for cancer trials that can affect the quality of
the study and limit cross-study comparisons.” [3]
The study titled “Does error and adverse event report-
ing by physicians and nurses differ?” found that of all the
events reported physicians only accounted for 1.1%,
while reporting by nurses accounted for 45.3%. The study
also found that physicians and nurses reported different
types of events. Showing physicians more often reported
events that “caused permanent harm, near death, or
death of the patient” and nurses more often reported
“events that caused no or temporary harm” [4]. Having a
system where the adverse events are collected systemati-
cally and well-documented within the patient’s chart can
improve the recognition, evaluation, and monitoring of
all adverse events by the entire patient care team [12,13].
A recent report compiled by the United States Depart-
ment of Health and Human Services’ Inspector General
identifed very common issues on AE reporting citing the
incomplete collection and information system related issues
[7]. Although Epic has the highest EHR marketshare [6],
our cancer clinics have determined that AE capture and
reporting features of Epic are not as functional as AERS
and are more difficult to track ongoing adverse events.
Another alternative could be to use some other existing AE
capture platforms; however, to our knowledge, there is no
available AE capture system in the public domain. caBIG
Adverse Event Reporting System (caAERS) [8] has been
developed by the National Cancer Institute; however, it is a
reporting system to generate necessary AE reports once an
AE is captured and it is not a AE capturing platform. Due
to those constraints, and since academic health centers
have their own diverse IT infrastructructure, AERS was cre-
ated to improve the efficacy of AE reporting at UAMS. The
AERS system integrates with the EHR allowing the infor-
mation to be documented within the patient encounter
note in the legal medical records. AERS is interfaced to a
research database as well and eliminates the need of the
clinical coordinator to retype AEs, thus preventing tran-
scription errors. Having the AE database and the EHR inte-
grated, the AERS system prompts the clinician to address
the ongoing AEs and note any changes. AERS will also
allow clinicians to address new AEs. The clinician will be
prompted to address all attributes regarding the ongoing or
new AEs to ensure the AEs are documented completely.
The AERS system has drastically improved AE reporting
efficacy and has helped eliminate unnecessary data queries
regarding data documentation by improving the data
collection process. By decreasing the AE queries, the effi-
ciency and accuracy of clinical trial management has
improved.
Methods
AERS was implemented as part of the Comprehensive
Research Informatics Suite (CRIS) at UAMS and inter-
faced with the Epic EHR to provide easy integration to
clinic workflows and properly document AEs in a patient’s
chart. As majority of academic health centers use Epic
EHR [6], we believe, integration schema defined in this
paper is easily adoptable. For non-Epic centers, the
approach is modeled after the way an external transcrip-
tion service would work, so it is possible for non-Epic
EHR customers to take advantage of the AERS.
CRIS
A novel component for biomedical informatics coordina-
tion efforts at UAMS is the adoption of common research
biomedical informatics systems; a goal toward which we
have already made unparalleled progress with CRIS
(Figure 1). Started as a Winthrop P. Rockefeller Cancer
Institute initiative, CRIS consists of 27 systems that are
integrated with an Enterprise Service Bus, with 23 tools
coming from open-source projects, mainly the National
Cancer Institute’s cancer Biomedical Informatics Grid
initiative and other public sources. CRIS is currently sup-
porting 419 studies and 346 users from 43 groups on cam-
pus. As a single platform, CRIS has three major benefits:
synergy, efficiency, and security. First, our experience has
been that functionality developed for research in one
domain (e.g., cancer research) nearly always benefits
research in other domains (e.g., pediatrics, geriatrics, etc.).
This has resulted in high levels of synergy in our work and
reduced the cost of biomedical informatics support for
research. Second, CRIS is a single platform that supports
the entire translational spectrum–from specimen manage-
ment applications for basic science research, to Phase 3 or
4 multi-site cancer trials. This enables researchers to move
ideas, data, results, technology, etc. from bench to bedside
more efficiently because they do not need to transition
experiments, studies, trials, technology, and data to new
software that might not be compatible with other
platforms. Third, as a single platform, CRIS is considerably
easier to secure because there is only one application for
each task. All components of CRIS are web based,
enabling sharing and integration of clinical research infor-
mation for single and multi-site trials.
All applications are integrated into a portal that allows a
single point of access with a registered UAMS username
and password. All CRIS applications reside on a cluster
server with failover capability behind the UAMS firewall,
and thus have the benefit of high security, fire protection,
and routine backup. CRIS modules are widely adopted
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across UAMS, and currently enhancing the suite to sup-
port their vanguard work in translating genomics and pro-
teomics research into clinical practice.
Symptoms and diagnosis
AERS has incorporated a systematic way to separate the
CTCAE into symptoms and diagnosis. When addressing
new AEs, AERS will not allow the clinician to select an
AE that is currently ongoing whether it was previously
documented as a symptom or a diagnosis to eliminate
duplicate reporting [10,11]. The adverse events listed in
the CTCAE version 4 are listed by system, and the items
are in alphabetical order. Since there are frequent syno-
nyms used in clinical medicine, if the correct medical
term does not come to mind it may be difficult to locate
the item that applies to the adverse event. We rearranged
the items in the same system heading by diagnosis (if the
diagnosis had an ICD 9 code) or otherwise by symptom.
In the diagnosis lists we further grouped the items under
headings. For example, valvular heart disease diagnoses
were under a subheading so titled and arrhythmias were
named in a different subheading. This made the adverse
events to be documented much easier to locate than an
alphabetical list (Figure 2).
AERS workflow
Current regulations require AEs to be captured and
reported in a timely and as accurate as possible manner
[1,7]. In order to increase the compliance, a user-
friendly system is required that demands a bidirectional
communication with the Epic EHR since Epic is the
starting point for a patient encounter (i.e. visit).
In order to pull complete and accurate patient demo-
graphics of those registered into a study, we developed an
interface to the caBIG Central Clinical Participant Registry
(C3PR), which serves as the UAMS’ research participant
registry. C3PR also houses study personnel who have been
approved to have access to participants’ records and AERS
authorizes the authenticated users and provides access to
study personnel listed in C3PR only. CLinicAl Research
Administrator (CLARA) is the UAMS’ Institutional
Review Board protocol management system that keeps
study metadata (e.g. name, ID etc.) as well as the investiga-
tional drugs and devices if it is an interventional study.
Figure 1 Vision for Clinical and Translational Research Operational Workflow.
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AERS pulls drug(s) or device(s) information from CLARA
so that a clinican may properly associate any AE to the
correct agent if AE is related.
There are two ways to create AEs in AERS: 1) Lab
AEs that are auto generated based on the study partici-
pants’ lab results (see section d;toxicity grading) and
2) office visits that are created by authorized users who
assess any new or worsening symptom a patient may
have due to study treatment (or pre-exisiting). In our
workflow, a study nurse assesses the ongoing AEs and
enters the new symptoms to make the system ready for
the provider to finalize the assessment. There are small
human interface reminders such as displaying a red
frame for ongoing AEs that are not assessed during the
visit yet to ensure all the ongoing AEs are designated as
either ongoing or resolved.
Upon login to AERS, a physician will be provided list
of awaiting assessments in a sidebar for easy access. The
system sends email reminders to the physicians if AEs
have not been finalized within 24 hours. The email
reminders are very useful in case of lab-based AEs since
lab results becomes available after an office visit and
associated documentation is completed.
After a provider approves/completes the AE asses-
ment, s/he is required to submit the assessment to the
EHR, reporting tool, and Electronic Case Report Forms.
Once the submit button is pressed, the system prompts
the provider to select a Customer Serial Number, which
is a unique identifier for each encounter in the Epic sys-
tem to import assessment into the correct progress
note. Customer Serial Numbers are stored in the CRIS’
Patient Study Calendar, which was sent by the Epic’s
scheduling HL7 messages. AERS will gather all asso-
ciated information from data sources of CRIS applica-
tions and generates documents by different assessment
dates, AE types, and providers, then sends out in a
defined format to Epic via HL7 and to the OpenClinica
(CRIS’ electronic case report form system) and caAERS
system utilizing MirthConnect’s web service and HL7
channels (Figure 3). MirthConnect is an open source
interface engine that manages CRIS’ all inter- and intra-
system messages.
Figure 2 Cardiac Disorders diagnosis list after re-categorization.
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Architecture of AERS
AERS is designed to be a modular and scalable platform
based on a multilayered architecture to accommodate a
new version of the grading criteria with ease (Figure 4).
At the operational management layer, it is running on a
Windows 2012 server with an Apache + MySQL + PHP
+ Perl (XAMPP) environment. At the security layer,
AERS verifies authentication against the Cental Authen-
tication System that is interfaced to UAMS’ Lightweight
Directory Access Protocol. At the service interface layer,
AERS has lab result, Epic EHR, OpenClinica, and
caAERS web services. Authorized users can easily create
new AEs that are categorized by affected systems, symp-
toms, and diagnoses. There are three user interfaces; 1)
Epic, at which they launch AERS and stores the assessed
AEs, 2) AERS where the assesment is completed, and 3)
Limesurvey where the grading information for each AE
is created. Since we use Limesurvey tool to create AE
and associated grades, it is easily extendable to newer
versions of CTCAE. Due to EHR changes, we had to
program CTCAE v3, and it was completed with approxi-
mately 80 hours of analyst time. MySQL is the database
for AERS as well as Limesurvey.
Toxicity grading
Given that many studies require lab results at all visits,
properly tracking and grading all the labs is a cumber-
some process and could be automated [5,9]. We have
developed an automated system that grades all the
numerically gradeable CTCAE labs and also record out-
of-range values. It then sends both sets of information
into the AERS so clinicians act upon them accordingly
(Figure 5).
A Minimal Lower Layer Protocol listener interface was
created using MirthConnect interface engine. Epic EDI
interface sends lab result messages to this interface as
HL7 file (File format: ORU - R01). Each HL7 message
goes through a different transformation and filtering
process after it is accepted by MirthConnect interface
engine. Upon receiving message, MirthConnect checks
with CRIS’ C3PR tool if the result belongs to one of the
clinical research participants. If the result belongs to a
subject, the MirthConnect starts parsing the HL7 mes-
sage and stores the information in a database. In the
next step, another transformation process sends this
results to the Cancer Automated Lab-based Adverse
Event Grading Service’s (CALAEGS)[5] web service.
This web service checks the result value, unit of mea-
surement, lab type, and low - high values by using the
predefined CTCAE rules and returns a grade as a
response. Grades can be 0, 1, 2, 3, 4, or 5. Our system
can process 28 different lab types out of 30 that are
defined in CALAEGS. Some of the lab types have two
defined Adverse Events. One for if the numeric value is
less than lower limit of normal and one for if the
numeric value is higher than upper limit of normal. For
the potassium test (K), lower limit of normal is 3.5
mEq/L and upper limit of normal is 5.1 mEq/L. There
are two defined adverse event for K. Those are hyperka-
lemia and hypokalemia. If result value is 3.3, the
numeric value is less than lower limit of normal. For
this case, defined CTCAE version 4.0 term is hypokale-
mia and the Medical Dictionary for Regulatory Activ-
ities’ version 12.0 code is 10021018. On the other hand,
if result value is 5.3, the numeric value is higher than
upper limit of normal. For this second case, defined
CTCAE v4.0 term is Hyperkalemia and the Medical Dic-
tionary for Regulatory Activities’ version 12.0 code is
10020647. Each adverse event is represented by the
Medical Dictionary for Regulatory Activities’ version
12.0 code. Responses coming from the CALAEGS web
service is stored in a database. Another batch process
Figure 3 AERS workflow.
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checks this database and sends graded lab results and out-
of-range lab results to the AERS web service for study
association determination by the clinicians (Figure 5).
There is also a lab and toxicity grading display interface
for users to see grades in order to perform possible over-
writes or grade (see Figure 6; K’s numeric value is normal;
however, additional information is needed for final grade,
such as hospitalization.)
Medical record integration and Epic interfaces
Epic supports Integrating the Healthcare Enterprise’s
Retrieve Process for Execution standard to enable provi-
ders to access research protocol with incoming messages
from clinical research systems. Retrieve Process for
Execution is one of a set of profiles that create interoper-
ability between EHRs and clinical research systems. The
study definition and the registration information are
being sent to Epic via Retrieve Process for Execution
from CRIS for all of the clinical research studies that are
being conducted at UAMS’ clinical enterprise. In addi-
tion, Epic has the bridge interfaces to allow incoming
HL7 messages such as transcriptions. We utilize the
research interface for AE documents, including lab-based
AEs that are being generated by AERS and sent to as
HL7 via the MirthConnect.
The workflow is as follows: in order to bring non-lab AE
documentation into Epic from AERS, first a documentation
note should be created with a visit, telephone, or documen-
tation encounter in Epic. Then select the Research tab in
the left navigational pane while in patient’s encounter.
Clicking the “Jump to AERS” link takes clinicians directly
to the patient’s ongoing assessment in AERS to ensure all
the existing AEs are assessed (Figure 7). Upon completion,
if there are additional symptoms (or diagnosis) to report,
Figure 4 AERS’ architecture layers.
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one should go the new AE tab within the AERS. The sys-
tem disables all the existing AE terms, and there is a “tool-
tip” displaying for each AE to give its description (Figure 8).
While adding a new AE, selecting the appropriate cus-
tomer serial number (i.e. encounter) from the dropdown
list is crucial to properly import incoming documents
into Epic. This allows the system to route the AERS note
to the appropriate encounter within Epic. Then the
“complete AERS button and submit” buttons are selected.
AERS documentation appears in the provider’s “in bas-
ket” folder in Epic, and must be signed by the provider.
After signing, it is possible to type ‘.aers’ within the
encounter note in Epic to pull in all signed non-lab
adverse event documentation for the encounter (Figure 9).
Lab-based AEs are filed as separate documents in Epic
and automatically routed to providers’ in basket for sig-
nature. They are then filed as Lab Based Adverse Event
note types in Epic.
Results and discussion
AERS has been directly implemented in more than 65
cancer studies and 350 patients on those studies within
Figure 5 Toxicity Grading Workflow.
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the UAMS oncology clinics. With the implementation of
the AERS system, we have seen several improvements in
the conduct of clinical trials. We have seen a decrease
in the time study coordinators spend to complete case
report forms related to adverse event reporting due to
complete AE assessments being available in timely man-
ner. The data is more organized, accurate, thorough,
and easily monitored by sponsors. With the AERS sys-
tem, electronic integration into the data collection data-
base for local investigator-initiated trials allows direct
upload of AE´s into the case report forms. This reduces
the need for the study coordinators to transcribe data,
and is the exact information electronically transcribed
from the source document, which improves accuracy in
data collection. The efficiencies and improvements that
are attributed to the AERS are listed in Table 1.
The reorganization of symptoms versus diagnoses and
the ability to see ongoing AEs at the time of entering a
possible new AE in AERS system decreases the chances of
documenting the same AE twice under different medical
synonyms. With the ability to place the AERS documenta-
tion in the encounter note, clinicians have an option to
use it as the documentation for the review of symptoms
section of the office visit. This eliminates descrepancies
and the use of medical synonyms for the same event,
which requires clarification in the note and queries to
Figure 6 Toxicity graded lab results view.
Figure 7 AERS ongoing AE assessment view.
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Figure 8 AERS new AE entry.
Figure 9 Imported AE into the Epic progress note.
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clarify the correct information. The combination of AERS
with our workflow has addressed the discrepancies noted
between nursing and physician assessments since the AEs
collected by all healthcare team members are assessed at
the same time with the same criteria, providing consis-
tency in reporting and reducing global introspection with
regard to assessing AEs. The feature that grades lab results
and imports that into AERS for final assessment and attri-
bution has saved much time and effort on the part of the
clinicians, research coordinators and monitors. The elimi-
nation of transcription has reduced errors as well.
The design of the AERS system allows multiple sites
to use the system for investigator initiated trials, thus
providing the same consistent reporting, accurate data
collection and improved efficacy of AE. With more
accurate AE reporting we will be able to improve accu-
racy and reduce time, thereby ultimately leading to
improved patient safety.
Conclusions
The AERS system, which is integrated globally into can-
cer clinical trials, improves the efficacy and speed of AE
reporting and promotes patient safety. The AERS system
provides a platform to globally standardize AE reporting,
ensuring consistent reporting, and will increase the effi-
ciency of the clinical trial staff. This has been accom-
plished through the flexibility allowed by the software
design with innovative integration of the open-source
tools and the ability to import the data into the com-
mercial EHR documentation. The flexible design may be
enhanced in the future to allow patient-reported events,
broadening the data collection further. We have used
open-source tools and systems and the source code is
available at https://github.com/vickiechen/AERS
List of abbreviations used
AE: Adverse Event; AERS: Adverse Event Reporting System; CALAEGS: Cancer
Automated Lab-based Adverse Event Grading Service; CLARA: CLinicAl
Research Administrator; CRIS: Comprehensive Research Informatics Suite;
CTCAE: Common Terminology Criteria for Adverse Events; EHR: Electronic
Health Record; HL7: Health Level 7; ICD: International Classification of
Diseases; K: Potassium; UAMS: University of Arkansas for Medical Sciences;
XAMPP: Apache + MySQL + PHP + Perl.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
AL: Has written the introduction and background of the paper. LH: Is the
subject matter expert and physician champion. Wrote sections for AE
clasification and benefits. SA: used AERS for regulatory and reporting and
provided some metrics for efficieny. WC: main AERS developer and provided
architectural figures. EE: grading and interface developer. Wrote the grading
section. ZF: technical lead and architect. KM: has done extensive testing and
provided many usability and medical/regulatory feedback. KS: measured
efficiency and tracked the metrics. Also used for monitoring purposes. CL:
oversight and support for the AERS development. UT: Led the AERS
implementation. Organized the paper and wrote implementation section of
the paper.
Acknowledgements
We would like to thank UAMS’ IT Clinical Systems and the Epic’s interface
team for their help and expertise during the implementation of the EHR
integration. We also thank Susan Van Dusen for proof-reading and edits.
Declarations
Publication of this work was partly supported by the Winthrop P. Rockefeller
Cancer Institute and Award UL1TR000039 from the National Center for
Advancing Translational Sciences.
This article has been published as part of BMC Bioinformatics Volume 16
Supplement 13, 2015: Proceedings of the 12th Annual MCBIOS Conference.
The full contents of the supplement are available online at http://www.
biomedcentral.com/bmcbioinformatics/supplements/16/S13.
Authors’ details
1Division of Hematology and Oncology, University of Arkansas for Medical
Sciences (UAMS), 4301 West Markham St., Little Rock, AR 72205, USA.
2Winthrop P. Rockefeller Cancer Institute, University of Arkansas for Medical
Sciences (UAMS), 4301 West Markham St., Little Rock, AR 72205, USA. 3IT
Research Systems, University of Arkansas for Medical Sciences (UAMS), 4301
West Markham St., Little Rock, AR 72205, USA. 4Division of Biomedical
Table 1 Improvements resulted by the AERS implementation.
# Area of improvement Estimated/actual improvement
1 Time spend for adverse event clarification between the
clinical trial office staff and providers
Estimated 60% less inquiries to clinics for clarification
2 All ongoing AEs are being assessed every visit The number of sponsor queries has decreased, which reduced the time needed to
identify and complete missed and incomplete assessments.
3 Complete and accurate reporting of AEs Staff spends less time to compile data from systems to complete needed attributes of
an AE report. This allows more thorough and accurate reporting.
4 Timely reporting of AEs As the complete and accurate AE report is easily available, the staff reports those in a
timely manner as expected by the sponsors and regulatory bodies.
5 Complete reporting of the lab related AEs Before AERS, the lab AE reporting was paper based with some potential missed lab-
based AEs. Each lab AE had to be signed by the provider with proper association. After
AERS, the research staff estimates that they are reporting 75% more lab-based AEs and
providers just make the clinical significance determination and submit electronically.
6 Time saving and efficiency due to less number of
queries.
We analyzed two studies and both of which have 10 subjects enrolled and the same
investigational product, the time frame is from April 2008 to the present date. A) Study
A that doesn’t use AERS, had 106 queries out of which 73 were AE related (~69%). B)
Study B that uses AERS, had 169 queries out of which 36 were AE related (27%)
The information is collected from the anecdotal and quantitative responses of the clinical trial office staff and the clinic staff
Lencioni et al. BMC Bioinformatics 2015, 16(Suppl 13):S6
http://www.biomedcentral.com/1471-2105/16/S13/S6
Page 10 of 11
Informatics, University of Arkansas for Medical Sciences (UAMS), 4301 West
Markham St., Little Rock, AR 72205, USA.
Published: 25 September 2015
References
1. CFR - Code of Federal Regulations Title 21. [http://www.accessdata.fda.
gov/SCRIPTs/cdrh/cfdocs/cfcfr/CFRSearch.cfm?fr=312.64].
2. Belknap SM, Georgopoulos CH, West DP, Yarnold PR, Kelly WN: Quality of
Methods for Assessing and Reporting Serious Adverse Events in Clinical
Trials of Cancer Drugs. Clinical Pharmacology & Therapeutics 2010,
88:231-236, doi: 10.1038/clpt.2010.79.
3. Nass JSharyl, Moses LHarold, Mendelsohn John: 3 Operations, Oversight,
and Funding of Cancer Clinical Trials. A National Cancer Clinical Trials
System for the 21st Century: Reinvigorating the NCI Cooperative Group
Program Washington, DC: The National Academies Press; 2010.
4. Rowin EJ, Lucier D, Pauker SG, Kumar S, Chen J, Salem DN: Does Error and
Adverse Event Reporting by Physicians and Nurses Differ? Jt Comm J
Qual Patient Saf 2008, 34:537-45.
5. Niland JC, Stiller T, Neat J, et al: Improving patient safety via automated
laboratory-based adverse event grading. J Am Med Inform Assoc 2012,
19:111-15.
6. Klas Research. [http://www.klasresearch.com/], accessed on 3/29/2015.
7. HHS’ Inspector General Report: Hospitals Incident Reporting Sytems do
not Capture Most Patient Harm.[https://oig.hhs.gov/oei/reports/oei-06-09-
00091.pdf], January 2012.
8. Speakman, John : The caBIG‚ Clinical Trials Suite. In Biomedical Informatics
for Cancer Research. Springer US;Ochs, Michael F., Casagrande, John T.,
Davuluri, Ramana V 2010:, 978-1-4419-5712-2.
9. Poon EG, Gandhi TK, Sequist TD, Murff HJ, Karson AS, Bates DW: “I wish I
had seen this test result earlier!": Dissatisfaction with test result
management systems in primary care. Arch Intern Med 2004,
164(20):2223-2228.
10. Graber ML, Franklin N, Gordon R: Diagnostic error in internal medicine.
Arch Intern Med 2005, 165(13):1493-1499.
11. Singh H, Naik A, Rao R, Petersen L: Reducing Diagnostic Errors Through
Effective Communication: Harnessing the Power of Information
Technology. Journal of General Internal Medicine 2008, 23(4):489-494.
12. Bates DW, O’Neil AC, Boyle D, et al: Potential identifiability and
preventability of adverse events using information systems. J Am Med
Inform Assoc 1994, 1:404.
13. Bates DW, Gawande AA: Improving patient safety with information
technology. N Engl J Med 2003, 348:2526-34.
doi:10.1186/1471-2105-16-S13-S6
Cite this article as: Lencioni et al.: An adverse event capture and
management system for cancer studies. BMC Bioinformatics 2015 16
(Suppl 13):S6.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color figure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Lencioni et al. BMC Bioinformatics 2015, 16(Suppl 13):S6
http://www.biomedcentral.com/1471-2105/16/S13/S6
Page 11 of 11
